Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) announced the appointment of Dr. Robert Scott to its Board of Directors, effective October 23, 2026. The company also increased the authorized number of directors on its Board from ten to eleven members. Dr. Scott has been appointed as a Class II director, with a term expiring at the Company’s 2028 annual meeting of stockholders.
Dr. Scott, age 73, is a veteran of the global pharmaceuticals industry with over 40 years of experience. Prior to his retirement in April 2020, he served as Chief Medical Officer and Head of Development at AbbVie Inc., where he was responsible for approximately 40 new molecular entities and 4,000 team members. During his tenure, AbbVie achieved over 14 major regulatory approvals, including Venclexta, Orilissa, Skyrizi, and Rinvoq. Before AbbVie, Dr. Scott held leadership roles at Amgen Inc., Cerenis Therapeutics, AtheroGenics, and Pfizer Inc., where he developed Lipitor and Norvasc. He also served as a non-voting industry representative on the U.S. Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee from 2012 to 2016.
Dr. Scott currently serves on the boards of directors for Confo Therapeutics, Draupnir Bio, Oncospherix, and Variant Bio. As a non-employee director, he will receive compensation in accordance with the Company’s non-employee director compensation program. Upon the effective date of his appointment, Dr. Scott received an initial stock option award exercisable for 20,507 shares of the Company’s common stock. He is also eligible for a prorated annual equity award fair valued at approximately $350,000 and a prorated annual cash retainer of $50,000 for Board service and $5,000 for service on the Nominating and Corporate Governance Committee.
